Israel Rubinstein, MD
Professor of Medicine
Department of Medicine, Division of Pulmonary, Critical Care, Sleep and Allergy
Email:
Related Sites:
About
List Accomplishments/Awards/Honor:
Dr Rubinstein holds several issued and pending US and international utility patents and has authored more than 300 peer-reviewed scientific papers. He is Clinical and Reviews Editor, Nanomedicine: Nanotechnology, Biology, and Medicine. Dr. Rubinstein co-founded ResQ Pharma, Inc. that has recently received a PDUFA date from U.S. FDA to complete the review of and make a decision on marketing approval of its LipidRescueTM Kit. He also co-founded EnSol Therapeutics, LLC that develops innovative medical countermeasures. Dr. Rubinstein was Board Member and Director of Advanced Life Sciences, a publicly-traded biopharmaceutical company in Woodridge, Illinois, focused on the discovery, development, and commercialization of drugs in the areas of infectious diseases, inflammation, and oncology.
Education
Medical School: Hebrew University, Jerusalem, Israel
Residency: The Chaim Sheba Medical Center, Tel-Hashomer, Israel
Fellowship: University of Toronto, Toronto, Ontario, Canada